Skip to content

Counterpulsation to Reduce Infarct Size pre-percutaneous coronary intervention (pre-PCI) for Acute Myocardial Infarction

A multi-centre, randomised controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size pre-percutaneous coronary intervention (pre-PCI) for acute myocardial infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN89012474
Enrollment
300
Registered
2008-12-10
Start date
2009-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction Circulatory System Acute myocardial infarction

Interventions

Patients will be randomised to recieve an intra-aortic balloon prior to primary percutaneous coronary intervention. The control group will be those patients randomised not to receive an intra-aortic b

Sponsors

Datascope Corp. (USA)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: To be eligible for this study, a subject must meet all of the following criteria: 1. Able to understand and sign an informed consent form (ICF) 2. Greater than or equal to 18 and less than or equal to 90 years of age, either sex 3. General good health, in the opinion of the investigator 4. ST elevation of greater than or equal to 2 mm in two contiguous anterior leads or greater than or equal to 4 mm total in anterior leads 5. Scheduled for PCI less than 6 hours from onset of symptoms of anterior MI

Exclusion criteria

Exclusion criteria: A subject who meets any of the following exclusion criteria will not be enrolled in the study: 1. Known contraindication to magnetic resonance imaging (MRI) 2. Prior thrombolytic therapy during the index event 3. Known history of MI 4. Prior coronary artery bypass graft surgery 5. Known severe aortic insufficiency 6. Known aortic aneurysm 7. Known severe calcific aorta-iliac disease or peripheral vascular disease 8. Experiencing cardiogenic shock 9. Known end-stage renal disease 10. Weight greater than 400 lbs or height less than 4 feet 11. Women of childbearing potential

Design outcomes

Primary

MeasureTime frame
1. Infarct size measured by MRI at 3 to 5 days post-PCI or at discharge, whichever comes first. The primary analysis population will be restricted to the subgroup of subjects with nondistal left anterior descending (LAD) lesion and thrombolysis in myocardial infarction (TIMI) flow of 0 or 1. 2. Other efficacy endpoints of importance: 2.1. Left ventricular ejection fraction (LVEF) 2.2. Microvascular obstruction (MVO) by MRI 2.3. Electrocardiogram (ECG) ST-segment resolution 90 minutes post-PCI 2.4. Left ventricular end-diastolic volume (LVEDV) 2.5. Left ventricular end-systolic volume (LVESV) 2.6. Salvage index by MRI

Secondary

MeasureTime frame
1. Vascular complications, defined as major limb ischaemia requiring operative intervention in the affected IAB limb after removal of the IAB 2. Amputation 3. Major bleed per GUSTO I definition, i.e., intracranial haemorrhage or bleeding that causes haemodynamic compromise and requires intervention 4. Major adverse cardiac events (MACE) within 24 hours of hospital admission, including: 4.1. Ventricular arrhythmias: VT, VF 4.2. Severe hypotension: systolic blood pressure (SBP) less than 90 mmHg for more than or equal to 5 minutes, requiring inotropic/pressor support medications or IV fluid 4.3. Cardiac arrest

Countries

Belgium, France, Germany, Ireland, Italy, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026